Tango Therapeutics (NASDAQ:TNGX – Get Free Report) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT – Get Free Report) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.
Profitability
This table compares Tango Therapeutics and Lakefront Biotherapeutics American Depositary Shares’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tango Therapeutics | N/A | -30.34% | -28.28% |
| Lakefront Biotherapeutics American Depositary Shares | N/A | N/A | N/A |
Analyst Ratings
This is a summary of current ratings and target prices for Tango Therapeutics and Lakefront Biotherapeutics American Depositary Shares, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tango Therapeutics | 2 | 2 | 13 | 0 | 2.65 |
| Lakefront Biotherapeutics American Depositary Shares | 0 | 5 | 2 | 1 | 2.50 |
Tango Therapeutics presently has a consensus price target of $48.17, indicating a potential upside of 117.85%. Lakefront Biotherapeutics American Depositary Shares has a consensus price target of $36.00, indicating a potential upside of 4.68%. Given Tango Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Tango Therapeutics is more favorable than Lakefront Biotherapeutics American Depositary Shares.
Institutional & Insider Ownership
79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Tango Therapeutics and Lakefront Biotherapeutics American Depositary Shares”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tango Therapeutics | $62.38 million | 60.06 | -$101.59 million | ($1.37) | -16.14 |
| Lakefront Biotherapeutics American Depositary Shares | $1.26 billion | 1.80 | $363.05 million | ($1.41) | -24.39 |
Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Tango Therapeutics. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Tango Therapeutics has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500.
Summary
Tango Therapeutics beats Lakefront Biotherapeutics American Depositary Shares on 9 of the 14 factors compared between the two stocks.
About Tango Therapeutics
Tango Therapeutics is a biotechnology company focused on discovering and developing precision medicines for cancer. Based in Cambridge, Massachusetts, the company aims to develop treatments that exploit genetic differences between cancer cells and healthy cells. Its research centers on synthetic lethality, an approach that seeks to identify vulnerabilities created when cancer cells lose or alter particular genes. Tango uses this strategy to find drug targets and develop investigational therapies for tumors with specific genetic alterations.
About Lakefront Biotherapeutics American Depositary Shares
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.
Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
